Abstract Intravenous thrombolytic therapy (IV) with recombinant tissue-plasminogen activator (alteplase; 0.9 mg/kg over 1h) is beneficial for acute ischaemic stroke patients with potentially disabling neurological deficits, and without contraindications, when…
Abstract Whereas only a minority of acute ischaemic stroke patients are eligible to reperfusion therapies, all can benefit from optimized supportive care to minimize acute stroke complications. Continuous pulse oximetry…
Abstract Most patients with suspected stroke should be transported without delay to a hospital, which has access to the required diagnostic tests and appropriate hyperacute treatments 24 h/day and 7…
Abstract Prehospital stroke care is the first link in the stroke chain of survival and includes symptom recognition, engagement of the Emergency Medical Services (EMS) system, timely and effective dispatcher…
Abstract Almost all efficacious stroke treatments confer moderate-to-large benefits, but not staggeringly huge benefits. However, moderate treatment effects can be clinically very worthwhile for the patient. To detect moderate-large treatment…
Abstract In the year 2010, an estimated 16.9 million strokes occurred worldwide at an incidence rate of 258 per 100,000 persons per year. Approximately 70% of these strokes occurred in…
